Protalix BioTherapeutics (NYSE:PLX) versus Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Review
by Kim Johansen · The Markets DailyProtalix BioTherapeutics (NYSE:PLX – Get Free Report) and Genocea Biosciences (NASDAQ:GNCAQ – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Protalix BioTherapeutics and Genocea Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalix BioTherapeutics | $76.38 million | 2.17 | $8.31 million | $0.18 | 11.42 |
| Genocea Biosciences | N/A | N/A | N/A | N/A | N/A |
Protalix BioTherapeutics has higher revenue and earnings than Genocea Biosciences.
Risk and Volatility
Protalix BioTherapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Protalix BioTherapeutics and Genocea Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Protalix BioTherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 483.94%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than Genocea Biosciences.
Profitability
This table compares Protalix BioTherapeutics and Genocea Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
| Genocea Biosciences | N/A | N/A | N/A |
Summary
Protalix BioTherapeutics beats Genocea Biosciences on 6 of the 11 factors compared between the two stocks.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.